Literature DB >> 23269395

Alternative PET tracers in head and neck cancer. A review.

Jan Wedman1, Jan Pruim, Jan L N Roodenburg, Gyorgy B Halmos, Johannes A Langedijk, Rudi A J O Dierckx, Bernard F A M van der Laan.   

Abstract

Positron emission tomography (PET) has become a standard in staging Head and Neck cancer. While (18)F-fluoro-2-deoxy-D-glucose (FDG) is the most frequently used radiopharmaceutical, glycolysis is not the only metabolic process that can be visualized. Different PET tracers can also be used to visualize other metabolic processes and in this manner, the disadvantages of FDG PET can be avoided. In this review, we describe a comprehensive overview of alternatives to FDG that can be used in identifying head and neck cancer. The potential advantages and disadvantages of these radiopharmaceuticals are discussed.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23269395     DOI： 10.1007/s00405-012-2316-9

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN： 0937-4477            Impact factor:   2.503


  49 in total

1.  Comparison of 18F-FDG and 11C-choline PET/CT for detecting recurrences in patients with nonsquamous cell head and neck malignancies.

Authors:  Kimiteru Ito; Jyunkichi Yokoyama; Kazuo Kubota; Miyako Morooka
Journal:  Nucl Med Commun       Date:  2010-11       Impact factor: 1.690

2.  Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.

Authors:  Susanne-Martina Eschmann; Frank Paulsen; Matthias Reimold; Helmut Dittmann; Stefan Welz; Gerald Reischl; Hans-Juergen Machulla; Roland Bares
Journal:  J Nucl Med       Date:  2005-02       Impact factor: 10.057

3.  Prospective comparison of FDG and FET PET/CT in patients with head and neck squamous cell carcinoma.

Authors:  S Balogova; S Périé; K Kerrou; D Grahek; F Montravers; B Angelard; B Susini; P El Chater; J Lacau St Guily; J N Talbot
Journal:  Mol Imaging Biol       Date:  2008-07-31       Impact factor: 3.488

4.  [18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer.

Authors:  Lukas B Been; Harald J Hoekstra; Albert J H Suurmeijer; Pieter L Jager; Bernard F A M van der Laan; Philip H Elsinga
Journal:  Oral Oncol       Date:  2009-08-18       Impact factor: 5.337

5.  Positron emission tomographic imaging with 11C-choline in differential diagnosis of head and neck tumors: comparison with 18F-FDG PET.

Authors:  Nasim Khan; Noboru Oriuchi; Hiroshi Ninomiya; Tetsuya Higuchi; Hideo Kamada; Keigo Endo
Journal:  Ann Nucl Med       Date:  2004-07       Impact factor: 2.668

6.  Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.

Authors:  Iris Verel; Gerard W M Visser; Ronald Boellaard; Otto C Boerman; Julliette van Eerd; Gordon B Snow; Adriaan A Lammertsma; Guus A M S van Dongen
Journal:  J Nucl Med       Date:  2003-10       Impact factor: 10.057

7.  Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG.

Authors:  R Kubota; K Kubota; S Yamada; M Tada; T Takahashi; R Iwata; N Tamahashi
Journal:  J Nucl Med       Date:  1995-03       Impact factor: 10.057

8.  Carbon-11 tyrosine PET for visualization and protein synthesis rate assessment of laryngeal and hypopharyngeal carcinomas.

Authors:  Jurjan R de Boer; Bernard F A M van der Laan; Jan Pruim; Tjin H Que; Fred Burlage; Allard Krikke; Antoon T M Willemsen; Anton T M G Tiebosch; Frans W J Albers; Willem Vaalburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-06-15       Impact factor: 9.236

9.  PET of EGFR antibody distribution in head and neck squamous cell carcinoma models.

Authors:  Gang Niu; Zibo Li; Jin Xie; Quynh-Thu Le; Xiaoyuan Chen
Journal:  J Nucl Med       Date:  2009-06-12       Impact factor: 10.057

10.  Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer.

Authors:  Daniela Thorwarth; Susanne-Martina Eschmann; Jutta Scheiderbauer; Frank Paulsen; Markus Alber
Journal:  BMC Cancer       Date:  2005-12-01       Impact factor: 4.430
View more
  2 in total

Review 1.  CD44v6-Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody-Based Approaches.

Authors:  Diana Spiegelberg; Johan Nilvebrant
Journal:  Contrast Media Mol Imaging       Date:  2017-06-20       Impact factor: 3.161

2.  The diagnostic value of 99TcM-2-(2-methyl-5-nitro-1H-imidazol-1-yl) ethyl dihydrogen phosphate hypoxia imaging and its evaluation performance for radiotherapy efficacy in non-small-cell lung cancer.

Authors:  Yongkun Yang; Gaohua Han; Wansong Xu
Journal:  Onco Targets Ther       Date:  2016-10-21       Impact factor: 4.147
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.